featured
Capmatinib for MET Exon 14–Mutated Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
Lancet Oncol 2024 Oct 01;25(10)1357-1370, J Wolf, M Hochmair, JY Han, N Reguart, PJ Souquet, EF Smit, SV Orlov, J Vansteenkiste, M Nishio, M de Jonge, W Akerley, EB Garon, HJM Groen, DSW Tan, T Seto, GM Frampton, A Robeva, M Carbini, S Le Mouhaer, A Yovine, A Boran, C Bossen, Y Yang, L Ji, L Fairchild, RS HeistFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.